Study to Evaluate the Safety and Efficacy of Switching From Zoladex® Monthly or Quarterly, to Eligard® Semiannual.
Status:
Completed
Trial end date:
2020-06-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, quality of life and safety of
switching from monthly (3.6 mg) or quarterly (10.8 mg) goserelin acetate (Zoladex®) to
semiannual leuprorelin acetate 45 mg (Eligard® 45 mg) in prostate cancer patients with
adequate hormonal castration level (plasma testosterone levels ≤50 ng/dL).